Indeed, preclinical and clinical data have shown that pharmacological inhibitors of HIF-2α can efficiently inhibit ccRCC growth (Meléndez-Rodríguez et al., 2018). The gene discussed is EPAS1; the disease is nonpapillary renal cell carcinoma.